Providing Answers, Support and Hope in the Southeastern US
UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug, VENT-03, for Lupus
Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study for people with systemic lupus erythematosus (SLE) in 2025.
The first drug of its kind to advance into clinical development, VENT-03 is an oral therapy designed to target and inhibit cGAS, a cell receptor linked to lupus and a broad range of other autoimmune diseases. The phase 1 trial examined pharmacokinetics , target engagement, safety and tolerability in 72 healthy adult volunteers. The results showed that VENT-03 was safe and well-tolerated at all tested dose levels with all treatment-related adverse events being mild and easily managed. VENT-03 exhibited a favorable pharmacokinetic profile, supporting once-daily dosing. Additionally, VENT-03 achieved plasma concentrations necessary for complete target inhibition and demonstrated strong pharmacodynamic (what a drug does to the body) effects.
Continue to follow the Lupus Foundation of America for updates lupus drug developments and clinical trials. Learn more about medications used to treat lupus.